US 9399775
RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
granted A61KA61K31/7125A61K31/713
Quick answer
US patent 9399775 (RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases) held by Alnylam Pharmaceuticals, Inc. expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 36
- CPC classes
- A61K, A61K31/7125, A61K31/713, A61P, A61P25/00